Skip to main content

Advertisement

SpringerLink
Log in

Effect of lifestyle interventions with or without metformin therapy on serum levels of osteoprotegerin and receptor activator of nuclear factor kappa B ligand in patients with prediabetes

  • Original Article
  • Published:
Endocrine Aims and scope Submit manuscript

Abstract

Osteoprotegerin has been shown to be increased in cardiovascular disorders and type 2 diabetes mellitus. Prediabetes represents a high risk condition for diabetes and diabetic complications. Therefore, we aimed to find the relationship between prediabetes and osteoprotegerin with nuclear factor–B ligand, carotid intima media thickness, and metabolic markers. A total of 54 participants with prediabetes including impaired fasting glucose (n = 21), impaired glucose tolerance (n = 8), impaired fasting glucose and impaired glucose tolerance (n = 25), and 60 healthy individuals as a control were admitted to the study. Metabolic and anthropometric parameters, insulin resistance variables, osteoprotegerin, and nuclear factor–B ligand markers, carotid intima media thickness were examined at baseline for all participants. To evaluate the effect of therapy we determined the same parameters after the end of the study. Measurements of waist circumference, body mass index, body fat percentage and levels of fasting blood glucose, fasting insulin, homeostatic model assessment of insulin resistance, triglyceride levels and hsCRP and carotid intima media thickness were significantly higher in patients with prediabetes (p < 0.05). We also found higher osteoprotegerin and lower nuclear factor–B ligand levels in patients than in controls however, the value was non-significant (p > 0.05). Patients with prediabetes were under lifestyle interventions with (group 1, n = 33) or without metformin (group 2, n = 21) therapy. Baseline anthropometric and metabolic characteristics were not found statistically different in group 1 and group 2. Mean follow up period of the patients were 7.9 ± 2.2 month (min-max: 6–12 months). After the follow up period we evaluated the same parameters and found significant differences between waist circumference, body mass index, body fat percentage, fasting insulin, homeostatic model assessment of insulin resistance, and osteoprotegerin levels (p < 0.05). However, carotid intima media thickness, and nuclear factor–B ligand levels significantly different only in the group treated with metformin (p < 0.05). We also compared the variables after the treatment period with the control group and found significantly lower levels in terms of fasting insulin, homeostatic model assessment of insulin resistance, waist circumference, body mass index, body fat percentage, carotid intima media thickness, osteoprotegerin, and nuclear factor–B ligand values (p < 0.05). Correlation analysis revealed a negative relationship between nuclear factor–B ligand and body mass index, and body fat percentage in group 1 (p = 0.05, r = −0.646, p = 0.01, r = −0.585). Therapy of prediabetes was associated with a significant decrease in osteoprotegerin and certain metabolic variables together with an increase in nuclear factor–B ligand levels particularly in patients with under metformin therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. S. Bord, E. Frith, D.C. Ireland, M.A. Scott, J.I. Craig, J.E. Compston, Synthesis of osteoprotegerin and RANKL by megakaryocytes is modulated by oestrogen. Br. J. Haematol. 126, 244–251 (2004)

    Article  CAS  PubMed  Google Scholar 

  2. U.M. Malyankar, M. Scatena, K.L. Suchland, T.J. Yun, E.A. Clark, C.M. Giachelli, Osteoprotegerin is an alpha vbeta 3-induced, NF-kappa B-dependent survival factor for endothelial cells. J .Biol. Chem. 275, 59–62 (2000)

    Article  Google Scholar 

  3. I. Lambrinoudaki, E. Tsouvalas, M. Vakaki, G. Kaparos, K. Stamatelopoulos, A. Augoulea, P. Pliatsika, A. Alexandrou, M. Creatsa, K. Karavanaki, Osteoprotegerin, soluble receptor activator of nuclear factor- κ b ligand, and subclinical atherosclerosis in children and adolescents with type 1 diabetes mellitus. Int. J. Endocrinol. 2013, 102120 (2013). doi:10.1155/2013/102120

    Article  PubMed  PubMed Central  Google Scholar 

  4. M. Waluś-Miarka, B. Katra, D. Fedak, D. Czarnecka, P. Miarka, E. Woźniakiewicz, M. Małecki, B. Idzior-Waluś, Osteoprotegerin is associated with markers of atherosclerosis and body fat mass in type 2 diabetes patients. Int. J. Cardiol. 147, 335–336 (2011). doi:10.1016/j.ijcard.2010.12.094

    Article  PubMed  Google Scholar 

  5. B. Erdogan, E. Aslan, T. Bagis, A. Gokcel, S. Erkanli, M. Bavbek, N. Altinors, Intima-media thickness of the carotid arteries is related to serum osteoprotegerin levels in healthy postmenopausal women. Neurol. Res. 26, 658–661 (2004)

    Article  PubMed  Google Scholar 

  6. M. Schoppet, J.R. Schaefer, L.C. Hofbauer, Low serum levels of soluble RANK ligand are associated with the presence of coronary artery disease in men. Circulation 107 (2003)

  7. S.M. Grundy, Pre-diabetes, metabolic syndrome, and cardiovascular risk. J. Am. Coll. Cardiol. 59, 635–643 (2012). doi:10.1016/j.jacc.2011.08.080

    Article  CAS  PubMed  Google Scholar 

  8. M. Kanat, R.A. DeFronzo, M.A. Abdul-Ghani, Treatment of prediabetes. World J. Diabetes 6, 1207–1222 (2015). doi:10.4239/wjd.v6.i12.1207

    PubMed  PubMed Central  Google Scholar 

  9. P. Secchiero, F. Corallini, A. Pandolfi, A. Consoli, R. Candido, B. Fabris, C. Celeghini, S. Capitani, G. Zauli, An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction. Am. J. Pathol. 169, 2236–2244 (2006)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. E.P. O’Sullivan, D.T. Ashley, C. Davenport, L. Penugonda, G. Kelleher, N. Devlin, R. Crowley, P. O’Shea, A. Agha, C.J. Thompson, D.J. O’Gorman, D. Smith, A comparison of osteoprotegerin with adiponectin and high-sensitivity C-reactive protein (hsCRP) as a marker for insulin resistance. Metabolism 62, 34–38 (2013). doi:10.1016/j.metabol.2012.06.005

    Article  PubMed  Google Scholar 

  11. American Diabetes Association. Classification and diagnosis of diabetes. Diabetes Care 38 (2015)

  12. D.R. Matthews, J.P. Hosker, A.S. Rudenski, B.A. Naylor, D.F. Treacher, R.C. Turner, Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 412–419 (1985)

    Article  CAS  PubMed  Google Scholar 

  13. American Diabetes Association, Standards of medical care in diabetes—2015. Diabetes Care 38(Suppl 1), S1–S93 (2015)

    Google Scholar 

  14. W.S. Browner, L.Y. Lui, S.R. Cummings, Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J. Clin. Endocrinol. Metab. 86, 631–637 (2001)

    CAS  PubMed  Google Scholar 

  15. G.D. Xiang, L. Xu, L.S. Zhao, L. Yue, J. Hou, The relationship between plasma osteoprotegerin and endothelium-dependent arterial dilation in type 2 diabetes. Diabetes 55, 2126–2131 (2006)

    Article  CAS  PubMed  Google Scholar 

  16. S. Jono, Y. Ikari, A. Shioi, K. Mori, T. Miki, K. Hara, Y. Nishizawa, Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 106, 1192–1194 (2002)

    Article  CAS  PubMed  Google Scholar 

  17. W. Lieb, P. Gona, M.G. Larson, J.M. Massaro, I. Lipinska, J.F. Keaney Jr, J. Rong, D. Corey, U. Hoffmann, C.S. Fox, R.S. Vasan, E.J. Benjamin, C.J. O’Donnell, S. Kathiresan, Biomarkers of the osteoprotegerin pathway: clinical correlates, subclinical disease, incident cardiovascular disease, and mortality. Arterioscler. Thromb. Vasc. Biol. 30, 1849–1854 (2010). doi:10.1161/ATVBAHA.109.199661

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. T. Ueland, S.G. Wilson, F.M. Amirul Islam, B. Mullin, A. Devine, J. Bollerslev, K. Zhu, R.L. Prince, A cohort study of the effects of serum osteoprotegerin and osteoprotegerin gene polymorphisms on cardiovascular mortality in elderly women. Clin. Endocrinol. (Oxf.) 71, 828–833 (2009)

    Article  CAS  Google Scholar 

  19. S. Kiechl, G. Schett, G. Wenning, K. Redlich, M. Oberhollenzer, A. Mayr, P. Santer, J. Smolen, W. Poewe, J. Willeit, Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 109, 2175–2180 (2004)

    Article  CAS  PubMed  Google Scholar 

  20. M. Ishiyama, E. Suzuki, J. Katsuda, H. Murase, Y. Tajima, Y. Horikawa, S. Goto, T. Fujita, J. Takeda, Associations of coronary artery calcification and carotid intima-media thickness with plasma concentrations of vascular calcification inhibitors in type 2 diabetic patients. Diabetes Res. Clin. Pract. 85, 189–196 (2009). doi:10.1016/j.diabres.2009.04.023

    Article  CAS  PubMed  Google Scholar 

  21. H. Parildar, O. Gulmez, O. Cigerli, A. Dogruk Unal, R. Erdal, N. Guvener Demirag, Carotid artery intima media thickness and hsCRP; predictors for atherosclerosis in prediabetic patients? Pak. J. Med. Sci. 29, 495–499 (2013)

    PubMed  PubMed Central  Google Scholar 

  22. U. Hostalek, M. Gwilt, S. Hildemann, Therapeutic use of metformin in prediabetes and diabetes prevention. Drugs 75, 1071–1094 (2015)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. W.C. Knowler, E. Barrett-Connor, S.E. Fowler, R.F. Hamman, J.M. Lachin, E.A. Walker, D.M. Nathan; Diabetes prevention program research group, reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346, 393–403 (2002)

    Article  CAS  PubMed  Google Scholar 

  24. R.R. Holman, S.K. Paul, M.A. Bethel, D.R. Matthews, H.A. Neil, 10-Year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J. Med. 359, 1577–1589 (2008)

    Article  CAS  PubMed  Google Scholar 

  25. C.J. Bailey, I.W. Campbell, J.C.N. Chan, J.A. Davidson, H.C.S. Howlett, P. Ritz Metformin, The gold standard: a scientific handbook. ed. by P. (Wiley, Chichester, UK, 2007) pp 135–152

  26. A. Esteghamati, M. Afarideh, S. Feyzi, S. Noshad, M. Nakhjavani, Comparative effects of metformin and pioglitazone on fetuin-A and osteoprotegerin concentrations in patients with newly diagnosed diabetes: a randomized clinical trial. Diabetes Metab. Syndr. 9, 258–265 (2015). doi:10.1016/j.dsx.2014.09.009

    Article  PubMed  Google Scholar 

  27. E.J. Rhee, W.Y. Lee, S.Y. Kim, B.J. Kim, K.C. Sung, B.S. Kim, J.H. Kang, K.W. Oh, E.S. Oh, K.H. Baek, M.I. Kang, H.Y. Woo, H.S. Park, S.W. Kim, M.H. Lee, J.R. Park, Relationship of serum osteoprotegerin levels with coronary artery disease severity, left ventricular hypertrophy and C-reactive protein. Clin. Sci. (Lond.) 108, 237–243 (2005)

    Article  CAS  Google Scholar 

Download references

Acknowledgments

This study was supported by the Department of Scientific Research and Projects belonging to the Diskapi Yildirim Beyazit Teaching and Research Hospital.

Author information

Authors and Affiliations

  1. Diskapi Training and Research Hospital, Department of Endocrinology and Metabolism, Ankara, Turkey

    Muyesser Sayki Arslan, Esra Tutal, Melia Karakose, Bekir Ucan, Erman Cakal & Mustafa Ozbek

  2. School of Medicine, Department of Endocrinology and Metabolism, Ankara University, Ankara, Turkey

    Mustafa Sahin

  3. Diskapi Training and Research Hospital, Department of Biochemistry, Ankara, Turkey

    Gulfer Ozturk

  4. Department of Biostatistics, School of Medicine, Ankara University, Ankara, Turkey

    Zeynep Biyikli Gencturk

  5. Department of Internal Medicine, School of Medicine (Kastamonu), Hacettepe University, Ankara, Turkey

    Tuncay Delibasi

Authors
  1. Muyesser Sayki Arslan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Esra Tutal
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mustafa Sahin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Melia Karakose
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Bekir Ucan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Gulfer Ozturk
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Erman Cakal
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Zeynep Biyikli Gencturk
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Mustafa Ozbek
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Tuncay Delibasi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Muyesser Sayki Arslan.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Arslan, M.S., Tutal, E., Sahin, M. et al. Effect of lifestyle interventions with or without metformin therapy on serum levels of osteoprotegerin and receptor activator of nuclear factor kappa B ligand in patients with prediabetes. Endocrine 55, 410–415 (2017). https://doi.org/10.1007/s12020-016-1121-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-016-1121-4

Keywords

Search

Navigation